Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Fineline Cube Jun 25, 2026
Company Deals

YHLO Biotech and Jingyi Bio Forge Strategic Alliance to Advance Neuroimmunology Diagnostics – Expanding Autoimmune Testing into Neurological Disorders

Fineline Cube Jun 24, 2026
Company Deals

Fusen Pharmaceutical Secures RMB 300M Strategic Investment for Henan Subsidiary Debt Restructuring and Working Capital

Fineline Cube Jun 24, 2026
Company Deals

AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline

Fineline Cube Jun 24, 2026
Company Deals

BioArctic Partners with Eli Lilly on Novel Neurodegenerative Disease Therapy Using BrainTransporter Platform

Fineline Cube Jun 23, 2026
Policy / Regulatory

China Launches 12th National Drug Volume-Based Procurement Batch with 65 Products, Patent Disputes Highlighted

Fineline Cube Jun 24, 2026
Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline

Fineline Cube Jun 25, 2026
Company Drug

Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP

Fineline Cube Jun 25, 2026
Company Deals

Boji Medical’s Huasheng Transfers Glucosamine Sulfate Capsules Technology to Panlong

Fineline Cube Mar 20, 2025

On March 20, 2025, Boji Medical Technology Co., Ltd (known as Boji Biomedicals) (SHE: 300404)...

Company Deals

Oxford BioTherapeutics Partners with Roche on Cancer Therapeutics Discovery

Fineline Cube Mar 20, 2025

On March 19, 2025, Oxford BioTherapeutics announced a multiyear collaboration with Roche (SWX: ROG, OTCMKTS:...

Company Drug

Joyo Pharma’s JYP0035 Receives Clinical Trial Approval for Breast Cancer Treatment

Fineline Cube Mar 20, 2025

On March 14, 2025, Joyo Pharma announced that its independently developed next-generation, highly selective Class...

Policy / Regulatory

CDE Announces 92nd Batch of Reference Preparations for Generic Drug Evaluation

Fineline Cube Mar 20, 2025

China’s Center for Drug Evaluation (CDE) has released the 92nd batch of reference preparations for...

Company

HutchMed’s 2024 Financial Report Shows Dip in Revenue Amid Oncology Product Growth

Fineline Cube Mar 20, 2025

China-based HutchMed (NASDAQ: HCM, HKG: 0013) released its 2024 financial report, revealing a total revenue...

Company Deals

Servier and Black Diamond Therapeutics Ink Global Deal for BDTX-4933

Fineline Cube Mar 20, 2025

French pharmaceutical company Servier and US-based Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) announced a strategic...

Policy / Regulatory

NMPA Seeks Public Input on Drug Trial Data Protection Measures

Fineline Cube Mar 20, 2025

On March 19, 2025, China’s National Medical Products Administration (NMPA) released draft measures and procedures...

Company Medical Device

Telix Pharmaceuticals Gains Brazilian Approval for Prostate Cancer Diagnostic Agent TLX591-CDx

Fineline Cube Mar 19, 2025

Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) announced receiving clearance from the Brazilian Health Regulatory Agency...

Company Deals Hospital

Distinct Healthcare Files for Hong Kong IPO to Expand Integrated Medical Services

Fineline Cube Mar 19, 2025

Shenzhen-based Distinct Healthcare Holdings Limited, a comprehensive medical service provider with integrated online and offline...

Company

Pfizer Restructures China Operations to Boost Growth and Innovation

Fineline Cube Mar 19, 2025

US-based pharmaceutical giant Pfizer Inc. (NYSE: PFE) announced a significant leadership and organizational restructuring in...

Policy / Regulatory

CDE’s 2024 Annual Drug Review Report Shows Continued Growth in Regulatory Filings

Fineline Cube Mar 19, 2025

The Center for Drug Evaluation (CDE) released its 2024 annual drug review report, highlighting continued...

Company

Everest Medicines Initiates Jiashan Plant for Etrasimod Tablet Production

Fineline Cube Mar 19, 2025

China-based Everest Medicines (HKG: 1952) announced the start of construction for a manufacturing plant in...

Company Deals

GE Healthcare and NVIDIA Expand Partnership to Advance Autonomous X-ray and Ultrasound Technologies

Fineline Cube Mar 19, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) announced an...

Company Drug

Tonghua Dongbao Initiates Phase III Trial for Insulin Degludec, Liraglutide Combo in Type 2 Diabetes

Fineline Cube Mar 19, 2025

China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) has initiated a Phase III clinical study for its...

Company Deals

Formosa Pharmaceuticals Inks Licensing Pact with Cipla for APP13007 in 11 Countries

Fineline Cube Mar 19, 2025

Taiwan-based Formosa Pharmaceuticals (TPE: 6838) announced a licensing agreement with India-headquartered Cipla Limited (BOM: 500087,...

Company Drug

AccurEdit Therapeutics Receives FDA Orphan Drug Designation for ATTR Treatment

Fineline Cube Mar 19, 2025

China-based AccurEdit Therapeutics (Suzhou) Co., Ltd announced receiving Orphan Drug Designation (ODD) from the US...

Company Drug

Johnson & Johnson’s Nipocalimab Receives FDA Fast Track Designation for Sjögren’s Disease

Fineline Cube Mar 19, 2025

US giant Johnson & Johnson (J&J; NYSE: JNJ) announced receiving Fast Track designation (FTD) from...

Company

Medbanks Reports 2024 Financial Results Amid Business Reorganization

Fineline Cube Mar 19, 2025

Sipai Health Technology Co., Ltd (HKG: 0314), known as Medbanks, released its 2024 financial report....

Company Drug

AstraZeneca’s Imfinzi Approved in EU for Limited-Stage Small Cell Lung Cancer

Fineline Cube Mar 19, 2025

UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) has received approval from the European Union (EU) for...

Company Drug

HutchMed and Innovent Announce Positive Results for Fruquintinib and Sintilimab in Renal Cell Carcinoma Trial

Fineline Cube Mar 19, 2025

Chinese companies HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) and Innovent Biologics, Inc. (HKG: 1801)...

Posts pagination

1 … 215 216 217 … 688

Recent updates

  • Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline
  • Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster
  • Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP
  • Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients
  • Henlius and Organon Canada Launch Denosumab Biosimilars BILDYOS and TUZEMTY – Expanding Access to Bone-Targeted Therapies Across All Canadian Indications
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline

Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Company Drug

Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP

Company Drug

Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.